Plant Advanced Technologies SA (ALPAT.PA)

EUR 11.7

(-2.5%)

Net Income Summary of Plant Advanced Technologies SA

  • Plant Advanced Technologies SA's latest annual net income in 2023 was 79.16 Thousand EUR , up 109.32% from previous year.
  • Plant Advanced Technologies SA's latest quarterly net income in 2023 FY was 79.16 Thousand EUR , up 109.32% from previous quarter.
  • Plant Advanced Technologies SA reported an annual net income of -849 Thousand EUR in 2022, up 25.13% from previous year.
  • Plant Advanced Technologies SA reported an annual net income of -1.13 Million EUR in 2021, down -108.84% from previous year.
  • Plant Advanced Technologies SA reported a quarterly net income of - EUR for 2023 Q2, down 0.0% from previous quarter.
  • Plant Advanced Technologies SA reported a quarterly net income of 202 Thousand EUR for 2022 Q4, down 0.0% from previous quarter.

Annual Net Income Chart of Plant Advanced Technologies SA (2023 - 2012)

Historical Annual Net Income of Plant Advanced Technologies SA (2023 - 2012)

Year Net Income Net Income Growth
2023 79.16 Thousand EUR 109.32%
2022 -849 Thousand EUR 25.13%
2021 -1.13 Million EUR -108.84%
2020 -543 Thousand EUR -0.33%
2019 -541.22 Thousand EUR -62705.58%
2018 864.51 EUR 228.11%
2017 -674.79 EUR 40.04%
2016 -1125.37 EUR -25.75%
2015 -894.93 EUR -50.5%
2014 -594.63 EUR 99.1%
2013 -66.02 Thousand EUR -125.46%
2012 259.34 Thousand EUR 0.0%

Peer Net Income Comparison of Plant Advanced Technologies SA

Name Net Income Net Income Difference
ABIONYX Pharma SA -3.51 Million EUR 102.25%
ABIVAX Société Anonyme -147.74 Million EUR 100.054%
Adocia SA -21.16 Million EUR 100.374%
Aelis Farma SA -5.07 Million EUR 101.559%
Biophytis S.A. -17.02 Million EUR 100.465%
Advicenne S.A. -7.03 Million EUR 101.126%
genOway Société anonyme 1.56 Million EUR 94.95%
IntegraGen SA -171.39 Thousand EUR 146.19%
Medesis Pharma S.A. -3.95 Million EUR 101.999%
Neovacs S.A. -8.74 Million EUR 100.905%
NFL Biosciences SA -3.74 Million EUR 102.114%
Quantum Genomics Société Anonyme -3.17 Million EUR 102.497%
Sensorion SA -22.06 Million EUR 100.359%
Theranexus Société Anonyme -6.82 Million EUR 101.159%
TME Pharma N.V. -6.73 Million EUR 101.175%
Valbiotis SA -7.36 Million EUR 101.074%
TheraVet SA -1.57 Million EUR 105.04%
Valerio Therapeutics Société anonyme -20.34 Million EUR 100.389%
argenx SE -272.91 Million EUR 100.029%
BioSenic S.A. -28.77 Million EUR 100.275%
Celyad Oncology SA -8.44 Million EUR 100.937%
DBV Technologies S.A. -67.26 Million EUR 100.118%
Galapagos NV 211.69 Million EUR 99.963%
Genfit S.A. -28.89 Million EUR 100.274%
GeNeuro SA -14.75 Million EUR 100.536%
Hyloris Pharmaceuticals SA -15.38 Million EUR 100.515%
Innate Pharma S.A. -7.57 Million EUR 101.046%
Inventiva S.A. -110.42 Million EUR 100.072%
MaaT Pharma SA -19.71 Million EUR 100.402%
MedinCell S.A. -25.03 Million EUR 100.316%
Nanobiotix S.A. -39.7 Million EUR 100.199%
Onward Medical N.V. -36.18 Million EUR 100.219%
Oryzon Genomics S.A. -3.35 Million EUR 102.361%
OSE Immunotherapeutics SA -23 Million EUR 100.344%
Oxurion NV -18.96 Million EUR 100.417%
Pharming Group N.V. -9.75 Million EUR 100.811%
Poxel S.A. -35.09 Million EUR 100.226%
GenSight Biologics S.A. -26.22 Million EUR 100.302%
Transgene SA -22.32 Million EUR 100.355%
Financière de Tubize SA 88.15 Million EUR 99.91%
UCB SA 343 Million EUR 99.977%
Valneva SE -101.42 Million EUR 100.078%
Vivoryon Therapeutics N.V. -28.34 Million EUR 100.279%